文献速递肺栓塞与肺血管病

肺动脉高压与慢性血栓栓塞性肺动脉高压的风险评估

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2019-06-05

本研究基于PATENT-1/2和CHEST-1/2研究数据,评估三种简化风险分层方法在PAH和CTEPH患者中的应用。结果显示利奥西呱治疗12周可改善PAH患者风险分层,法国无创法和瑞典/COMPERA法可区分基线和随访时的生存及无临床恶化生存,达到低风险标准的患者预后更好。

要点

  • 利奥西呱治疗12周可改善PAH患者风险分层。
  • 法国无创法和瑞典/COMPERA法可区分基线和随访预后。
  • 达到低风险标准者死亡和临床恶化风险显著降低。

核心结论

  • 分析证实并扩展了注册研究结果,支持PAH目标导向治疗的价值。
  • 对CTEPH患者需进一步评估这些方法。

研究设计与样本

  • 基于PATENT-1/2和CHEST-1/2研究的患者数据,评估三种简化风险分层方法。
  • 在PATENT-1和CHEST-1基线和随访时评估风险。

主要发现

  • 三种方法均显示利奥西呱治疗12周后PAH患者风险分组/分层改善。
  • 法国无创法和瑞典/COMPERA法在基线和随访时均可区分生存和无临床恶化生存。
  • 随访时达到一个或多个低风险标准或低风险层的患者,死亡和临床恶化风险显著降低。
  • 在不可手术或持续/复发性CTEPH患者中获得相似结果。

临床怎么用

  • 可采用简化风险分层方法评估PAH患者预后并指导目标导向治疗。
  • CTEPH患者应用这些方法需进一步评估。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current pulmonary hypertension treatment guidelines recommend use of a risk stratification model encompassing a range of parameters, allowing patients to be categorised as low, intermediate or high risk. Three abbreviated versions of this risk stratification model were previously evaluated in patients with pulmonary arterial hypertension (PAH) in the French, Swedish and COMPERA registries. Our objective was to investigate the three abbreviated risk stratification methods for patients with mostly prevalent PAH and chronic thromboembolic pulmonary hypertension (CTEPH), in patients from the PATENT-1/2 and CHEST-1/2 studies of riociguat. METHODS: Risk was assessed at baseline and at follow-up in PATENT-1 and CHEST-1. Survival and clinical worsening-free survival were assessed in patients in each risk group/strata. RESULTS: With all three methods, riociguat improved risk group/strata in patients with PAH after 12 weeks. The French non-invasive and Swedish/COMPERA methods discriminated prognosis for survival and clinical worsening-free survival at both baseline and follow-up. Furthermore, patients achieving one or more low-risk criteria or a low-risk stratum at follow-up had a significantly reduced risk of death and clinical worsening compared with patients achieving no low-risk criteria or an intermediate-risk stratum. Similar results were obtained in patients with inoperable or persistent/recurrent CTEPH. CONCLUSIONS: This analysis confirms and extends the results of the registry analyses, supporting the value of goal-oriented treatment in PAH. Further assessment of these methods in patients with CTEPH is warranted.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Humbert M, Farber HW, Ghofrani HA, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019. PMID: 30923187. doi:10.1183/13993003.02004-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。